These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27271685)

  • 1. Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer.
    Sahoo B; Arduini I; Drombosky KW; Kodali R; Sanders LH; Greenamyre JT; Wetzel R
    PLoS One; 2016; 11(6):e0155747. PubMed ID: 27271685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
    Wetzel R
    Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo.
    Legleiter J; Mitchell E; Lotz GP; Sapp E; Ng C; DiFiglia M; Thompson LM; Muchowski PJ
    J Biol Chem; 2010 May; 285(19):14777-90. PubMed ID: 20220138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis implicates the amyloid fibril as the toxic entity in Huntington's disease.
    Drombosky KW; Rode S; Kodali R; Jacob TC; Palladino MJ; Wetzel R
    Neurobiol Dis; 2018 Dec; 120():126-138. PubMed ID: 30171891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Targetable Self-association Surface of the Huntingtin exon1 Helical Tetramer Required for Assembly of Amyloid Pre-nucleation Oligomers.
    Mishra R; Gerlach GJ; Sahoo B; Camacho CJ; Wetzel R
    J Mol Biol; 2024 Jun; 436(12):168607. PubMed ID: 38734203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibril polymorphism affects immobilized non-amyloid flanking domains of huntingtin exon1 rather than its polyglutamine core.
    Lin HK; Boatz JC; Krabbendam IE; Kodali R; Hou Z; Wetzel R; Dolga AM; Poirier MA; van der Wel PCA
    Nat Commun; 2017 May; 8():15462. PubMed ID: 28537272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments.
    Jayaraman M; Kodali R; Sahoo B; Thakur AK; Mayasundari A; Mishra R; Peterson CB; Wetzel R
    J Mol Biol; 2012 Feb; 415(5):881-99. PubMed ID: 22178474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of mutant Huntingtin aggregates and toxicity by human myeloid leukemia factors.
    Banerjee M; Datta M; Bhattacharyya NP
    Int J Biochem Cell Biol; 2017 Jan; 82():1-9. PubMed ID: 27840155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregation behavior of chemically synthesized, full-length huntingtin exon1.
    Sahoo B; Singer D; Kodali R; Zuchner T; Wetzel R
    Biochemistry; 2014 Jun; 53(24):3897-907. PubMed ID: 24921664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid-State Nuclear Magnetic Resonance on the Static and Dynamic Domains of Huntingtin Exon-1 Fibrils.
    Isas JM; Langen R; Siemer AB
    Biochemistry; 2015 Jun; 54(25):3942-9. PubMed ID: 26020223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.
    Chen M; Wolynes PG
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4406-4411. PubMed ID: 28400517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the Molecular Complexity of N-Terminus Huntingtin Oligomers: Insights into Polymorphic Structures.
    Nanajkar N; Sahoo A; Matysiak S
    J Phys Chem B; 2024 Aug; 128(32):7761-7769. PubMed ID: 39092631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polyglutamine domain is the primary driver of seeding in huntingtin aggregation.
    Skeens A; Siriwardhana C; Massinople SE; Wunder MM; Ellis ZL; Keith KM; Girman T; Frey SL; Legleiter J
    PLoS One; 2024; 19(3):e0298323. PubMed ID: 38483973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SUMOylation Prevents Huntingtin Fibrillization and Localization onto Lipid Membranes.
    Sedighi F; Adegbuyiro A; Legleiter J
    ACS Chem Neurosci; 2020 Feb; 11(3):328-343. PubMed ID: 31880908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntingtin disrupts lipid bilayers in a polyQ-length dependent manner.
    Burke KA; Hensal KM; Umbaugh CS; Chaibva M; Legleiter J
    Biochim Biophys Acta; 2013 Aug; 1828(8):1953-61. PubMed ID: 23643759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Terminal Fragments of Huntingtin Longer than Residue 170 form Visible Aggregates Independently to Polyglutamine Expansion.
    Chen MZ; Mok SA; Ormsby AR; Muchowski PJ; Hatters DM
    J Huntingtons Dis; 2017; 6(1):79-91. PubMed ID: 28339398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of neurotoxic HTTex1 assemblies in human neurons.
    Chongtham A; Isas JM; Pandey NK; Rawat A; Yoo JH; Mastro T; Kennedy MB; Langen R; Khoshnan A
    Neurobiol Dis; 2021 Nov; 159():105517. PubMed ID: 34563643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-Degrading Enzyme Efficiently Degrades polyQ Peptides but not Expanded polyQ Huntingtin Fragments.
    Geijtenbeek KW; Aranda AS; Sanz AS; Janzen J; Bury AE; Kors S; Al Amery N; Schmitz NCM; Reits EAJ; Schipper-Krom S
    J Huntingtons Dis; 2024; 13(2):201-214. PubMed ID: 38640164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoscale studies link amyloid maturity with polyglutamine diseases onset.
    Ruggeri FS; Vieweg S; Cendrowska U; Longo G; Chiki A; Lashuel HA; Dietler G
    Sci Rep; 2016 Aug; 6():31155. PubMed ID: 27499269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.